Routine Continuous Monitoring After Angioplasty Might Not Be Necessary

According to a recent study published in Circ. Cardiovasc Interv, after a scheduled angioplasty, the rate of arrhythmia requiring some kind of treatment is very low, low enough to deem unnecessary the routine monitoring of all patients.

Monitoreo Post Angioplastia

The standard policy at many institutions is continuous cardiac monitoring for several hours after undergoing coronary angioplasty, with its subsequent discomfort and monetary costs.

More thorough monitoring of patients who are at risk for arrhythmia seems a reasonable strategy. The at-risk group might include patients with acute coronary syndrome, left main or multivessel disease, hemodynamic instability, and patients with “less than perfect” angioplasty outcomes.

This study included 1278 consecutive procedures between 2015 and 2017. According to hospital policy, all angioplasties were followed by cardiac monitoring for a mean 24 hours. For this analysis, patients were divided in groups depending on whether they experienced arrhythmia requiring treatment or not.


Read also: Reliability of FFR in Patients with Diabetes: Are Other Parameters Necessary?


Overall, there were 1672 arrhythmias during the post-procedure period. Among them, only 37 (2.2%) were actual medically actionable alarms. There were 20 cases of bradyarrhythmia and 17 cases of tachyarrhythmia, with an average of 5.5 hours post-procedure.

Patient factors associated with arrhythmia requiring treatment were acute coronary syndrome, older age, left main disease, and multivessel disease.

Among patients with arrhythmia, 30-day mortality was 6.5% vs. 0.3% for those with no arrhythmia (p < 0.0001).


Read also: New European Guidelines for Dyslipidemia Management: What is New?


Additionally, having an arrhythmia alarm activated was associated with permanent pacemaker and implantable cardioverter-defibrillator, patient transfer to a coronary unit, and use of class I and III antiarrhythmic drugs.

The results of this work are more hypothesis-generating than definitive. Many physicians might voice some concerns (even of legal nature) about not monitoring patients after angioplasty.

Original Title: Routine continuous electrocardiographic monitoring following percutaneous coronary interventions.

Reference: Al-Hijji MA et al. Circ Cardiovasc Interv. 2020;13:e008290.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI) remains a major clinical challenge. These...

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed that caffeine could trigger atrial fibrillation (AF)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...